Skip to main content
. 2021 Aug 21;11(8):820. doi: 10.3390/jpm11080820

Figure 2.

Figure 2

The status of different drugs under development that target lipid metabolism. ABCA1/ABCG1: ATP binding cassette subfamily A/G member 1; APOL1: Apolipoprotein L1; CD36: cluster of differentiation 36; FXR: farnesoid X receptor; LXR: liver X receptor; PCSK9: pro-protein convertase subtilisin/kexin type 9; PPAR: proliferator-activated receptor; SREBP: sterol regulatory element-binding protein.